Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EU 2019 Approvals: Novel Therapies Make Strong Showing

Firsts Include Ebola Vaccine And Tumor Agnostic Therapy

Jan 14 2020

• By Ian Schofield

Pink Sheet Perspectives 2019 to 2020 — 2019 saw the EU approval of several new innovative drugs

Related Content

First Ebola Vaccine Among Seven Products To Get EMA Nod

Oct 18 2019

New EU Approvals

Dec 04 2019

Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay

Jun 24 2019

Astellas Gets Europe Okay For AML Drug Xospata

Oct 28 2019

Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment

Sep 24 2019

EU Approvals: Evenity Cleared For Severe Osteoporosis

Dec 12 2019

Related Companies

Genetix Biotherapeutics

Merck & Co., Inc.

Bayer AG

Akcea Therapeutics, Inc.

Ionis Pharmaceuticals, Inc.

AbbVie Inc.

BioMarin Pharmaceutical Inc.

Portola Pharmaceuticals, Inc.

Astellas Pharma, Inc.

AOP Orphan Pharmaceuticals AG

Regeneron Pharmaceuticals, Inc.

Sanofi

Pfizer Inc.

Johnson & Johnson

Theratechnologies Inc.

Lexicon Pharmaceuticals, Inc.

Dova Pharmaceuticals, Inc.

Shionogi & Co. Ltd.

Alexion Pharmaceuticals Inc.

Novo Nordisk A/S

Teva Pharmaceutical Industries Ltd.

La Jolla Pharmaceutical Company

UCB S.A.

Amgen, Inc.

Aerie Pharmaceuticals, Inc.

Additional Topics

Europe Approvals Regulation BioPharmaceutical Pink Sheet Perspectives

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window